Biologic Augmentation of TMJ Arthroscopy Using BMAC
Part of paid clinical trials in New York, New York.
- Sponsor
- Weill Medical College of Cornell University
- Study ID
- NCT07536399
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Oral and Maxillofacial Conditions
- TMJ - Oral &Maxillofacial Surgery
- TMJ Arthralgia
- TMJ Pain
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Bone Marrow Aspirate Concentrate — BIOLOGICALSingle dose injection of bone marrow fluid from the participant's anterior iliac crest (hip) into the TMJ area during arthroscopy.
- Corticosteroid (CS) — DRUGSingle dose injection of cortiosteroid into the TMJ area during arthroscopy.
Study Details
The goal of this clinical trial is to learn about the efficacy of using Bone Marrow Aspirate Concentrate (BMAC) during temporomandibular joint (TMJ) arthroscopy compared to standard arthroscopic procedures with corticosteroid (CS) injections in patients with pain (arthralgia) of the temporomandibular joint (TMJ) that has failed to respond to conservative treatment. The main question it aims to answer: Does BMAC injection reduce the amount of inflammation and structural damage in the TMJ? Researchers will compare BMAC injection to corticosteroid injections see if BMAC injection helps . Participants will : * Be randomized to receive either BMAC or CS injection during TMJ arthroscopy * Visit the clinic for 3 follow up visits over 6 months and answer questionnaires * have 2 MRIs of their jaw
Key Dates
- First listed
- Apr 17, 2026
- Start date
- May 1, 2026
- Status verified
- Jul 2026
- Primary completion
- Dec 31, 2027
- Completion
- Jun 30, 2028
Study Design
- Enrollment
- 20 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: BMAC ArmParticipants in this arm will receive BMAC injection during their TMJ arthroscopy procedure
- Active Comparator: Corticosteroid ArmParticipants in this arm will receive steroid injection during their TMJ arthroscopy procedure
Primary Outcome Measure
Change from Baseline in Kellenberger score at 6 Months. [ Time Frame: Baseline; 6 months ]
Central Contacts
- Jordan Augsburger212.746.5175
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Weill Cornell Medical College - NewYork-Presbyterian Hospital | New York | New York | 10024 |
Find similar trials in New York, NY
Related Studies
- Topical Treatment for TMJ ArthralgiaPHASE3 · Recruiting · University of the Pacific · San Francisco, California
- A Double-blind, Placebo-controlled Evaluation of the Effect of the Erchonia® EVRL on Chronic Jaw Pain Arising From TMJRecruiting · Erchonia Corporation · Acton, Massachusetts